The natural logarithmic scale (base 10) of the number of G. pallidipes per trap per day for each observation (i.e., trap per period) plotted against their distance from the reserve... by Stella Gachoki (16024540)

Viral inhibition assays around the IC50 of VPA by direct inhibition of HDAC2. by Amanda Watson (4447267)

Determination of IC₅₀ and maximum induction of VPA using Vero cells. by Amanda Watson (4447267)

Confidence intervals for physiological regions. by Inmaculada Villanueva-Baxarias (21454246)

Water isotopes and carbon, nitrogen, and phosphorus species during the observation period categorized by burn status and land use. by Trevor Crandall (11302250)

Inter-individual variation in tonic ISG RNA expression in human tissues. by Tyron Chang (9922533)

Predicted analysis of time-to-treatment initiation beyond 2.7 weeks from diagnosis among Black and White patients. by Lohuwa Mamudu (14312658)

Host cellular genes interactions with the SARS-CoV2 proteins. by Amanda Watson (4447267)

Effect of different polyunsaturated fatty acids (PUFAs) in the inhibition of HCoV-229Eviral replication in MRC5 cells using antibody-based assay demonstrates significant inhibition... by Amanda Watson (4447267)

Scatter plots of the molecular pathways obtained from ingenuity pathway analysis (IPA) under different treatment combinations of DHA and VPA. by Amanda Watson (4447267)

Glucose/galactose regulation of IFN-γ induced IRF1 protein is conserved in mammals. by Tyron Chang (9922533)

EdU⁺/CC-1⁺ cells are present to at least 3 months post-TBI. by Krista A. Dent (709531)

Image 1_Ketogenic diet–induced changes in methylation status and neuropeptide signaling: relationships between S-adenosylmethionine (AdoMet), orexin-A, and metabolic health.pdf by Laura Mosca (704904)

“…</p>Results<p>After 8 weeks, participants exhibited significant reductions in body weight, BMI, visceral adipose tissue, total cholesterol, fasting glycemia, triglycerides, and HbA1c (all p < 0.05). Circulating AdoMet (−75.7%) and Orexin-A (−7.2%) levels also decreased significantly. …”

Olig2 cells in external capsule at 48h and 5 weeks after TBI. by Krista A. Dent (709531)

“…<p>Brain sections were immunostained for Olig2 and counterstained with DAPI. Panels show (A,C) contralateral and (B,D) ipsilateral external capsule (EC) at (A,B) 48h and (C,D) 5 weeks (5wk) post-TBI. …”

Proliferative Olig2 cell numbers increase within 2d after TBI and remain elevated to at least 3 months. by Krista A. Dent (709531)

“…(D) In the ipsilateral external capsule, numbers of EdU⁺/Olig2⁺ oligodendrocytes were significantly increased within 2d after injury, were further increased at 1 and 2 weeks, with lower numbers by 3 months. (E) A significant increase in EdU⁺ oligodendrocytes was also detected in the corpus callosum between 2d and 1 week, decreasing to control levels by 2 weeks. …”

Influence of the order of addition of fusing partners on HCVpp 1a fusion inhibition by Arb. by Elodie Teissier (232354)

“…a<p>Arb (11.3 µM) was pre-incubated sequentially with either HCVpp or R₁₈-labeled liposomes or both for the indicated times at 37°C before initiating lipid mixing by decreasing pH to 5.0 as described in the legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015874#pone-0015874-g002" target="_blank">Figure 2</a>. …”

Table_2_Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis.DOC by Alanna C. Cote (9966464)

“…Participants with dementia demonstrated lower levels of daily activity (standardized mean difference (SMD), −1.60; 95% CI, −2.66 to −0.55), decreased sleep efficiency (SMD, −0.52; 95% CI, −0.89 to −0.16), and greater intradaily circadian variability (SMD, 0.46; 95% CI, 0.27 to 0.65) than controls, among other measures. …”

Table_1_Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis.DOC by Alanna C. Cote (9966464)

“…Participants with dementia demonstrated lower levels of daily activity (standardized mean difference (SMD), −1.60; 95% CI, −2.66 to −0.55), decreased sleep efficiency (SMD, −0.52; 95% CI, −0.89 to −0.16), and greater intradaily circadian variability (SMD, 0.46; 95% CI, 0.27 to 0.65) than controls, among other measures. …”

Table_2_Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis.DOC by Alanna C. Cote (9966464)

“…Participants with dementia demonstrated lower levels of daily activity (standardized mean difference (SMD), −1.60; 95% CI, −2.66 to −0.55), decreased sleep efficiency (SMD, −0.52; 95% CI, −0.89 to −0.16), and greater intradaily circadian variability (SMD, 0.46; 95% CI, 0.27 to 0.65) than controls, among other measures. …”

Table_1_Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis.DOC by Alanna C. Cote (9966464)

“…Participants with dementia demonstrated lower levels of daily activity (standardized mean difference (SMD), −1.60; 95% CI, −2.66 to −0.55), decreased sleep efficiency (SMD, −0.52; 95% CI, −0.89 to −0.16), and greater intradaily circadian variability (SMD, 0.46; 95% CI, 0.27 to 0.65) than controls, among other measures. …”